Wealth of Nations Podcast
Before the start of the COVID-19 pandemic, the global health crisis that kept the most public health experts up at night was the rise of antimicrobial resistant (AMR) microbes. According to the World Health Organization, 700,000 [https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf] people lose their lives to multi-drug resistant microbes a year. If no steps are taken to control the growth of AMR microbes, 10 million people a year could die from AMR microbes, more than times the number of people killed by COVID-19. Basic medical procedures we take for granted, such as knee surgeries, would start carrying the risk of deadly sepsis. Today the superbug crisis is most visible in the developing world [https://www.thenews.com.pk/print/444010-pakistan-among-countries-with-highest-levels-of-antimicrobial-resistance-study], where high levels of infectious disease spread and systematic misuse of medication is highest. According to the CDDEP, India has one of the highest rates [http://Global Trends in Antimicrobial Resistance in Animals in Low- and Middle-Income Countries] of antimicrobial resistance in the world. My own grandfather lost his life to a hospital acquired antibiotic resistant drug last year. Today 60,000 children [https://www.downtoearth.org.in/blog/health/what-should-india-do-to-control-antimicrobial-resistance-74267#:~:text=The%20containment%20of%20antimicrobial%20resistance,resistant%20to%20first%20line%20antibiotics.] die of AMR sepsis every year, and it is estimated deaths from AMR microbes will increase to 2 million a year by 2050. Today’s podcast episode will explore why AMR microbes have become such a huge problem in India, some of the consequences of the rise of AMR, and the steps taken by the Indian government to bring AMR microbes under control. The Rise of Superbugs in India One of the major advantages bacteria have against humans in our fight to control them is the speed at which they replicate. Many bacteria can double their population in under 20 minutes under ideal conditions [https://vlab.amrita.edu/?sub=3&brch=73&sim=1105&cnt=1#:~:text=The%20time%20taken%20by%20the,aureus%20it%20is%2030%20minutes.]. As a result, bacteria rapidly evolve defense mechanisms against whatever medications we develop to combat them. The first effective antibiotics, sulfamides, were discovered in 1937. The first cases of antibiotic resistance [https://mmbr.asm.org/content/74/3/417] emerged in just two years. We have since then been locked in a cycle of discovering new drugs, and the effectiveness of these drugs reduced by antimicrobial resistance since then. The risk of bacteria gaining resistance increases if an antibiotic course is not completed, or if bacteria face trace amounts of antibiotics in the environment. Bacteria that face antibiotics have evolutionary pressure to gain defenses against antibiotics, and the more often bacteria face antibiotics but are not killed by them, the graeter the chances of resisistance arising. One of the major forces making AMR bacteria such a major problem in developing countries such as India is poor prescribing habits. From anecdotal experience, many doctors in India have only a limited understanding of the risks of over-prescribing antibiotics. Moreover, India today has [https://data.worldbank.org/indicator/SH.MED.PHYS.ZS?most_recent_value_desc=true] only.9 physicians per 100,00 people, only one third the physicians per capita as the United States, with the shortage [https://scroll.in/article/970941/interview-shortage-of-doctors-in-rural-india-will-hamper-effective-response-to-covid-19-pandemic#:~:text=More%20than%2060%25%20of%20India's,health%20centres%20in%20rural%20areas.]far more severe in rural areas. As a result, pharmacists are the first medical providers many Indians go to, to receive medical treatment. However, three quarters of pharmacists have no training. Most engage in practices such as offering antibiotics as a prophylactic during the winter, prescribing antibiotics for common colds where they are unlikely to be useful, or only giving partial courses of antibiotics to save poor sick people money. Antibiotic misuse expands beyond human use of antibiotics. India has one of the world’s largest herds of livestock in the world. India has a total cattle inventory of over 300 million cows, with large numbers of chicken, pigs and other animals. Antibiotics are often used [https://www.who.int/news/item/07-11-2017-stop-using-antibiotics-in-healthy-animals-to-prevent-the-spread-of-antibiotic-resistance] liberally to treat animal diseases, with many receiving antibiotics as prophylactics or to accelerate growth. Currently about 70% [https://www.cidrap.umn.edu/news-perspective/2016/12/fda-antibiotic-use-food-animals-continues-rise#:~:text=Approximately%2070%25%20of%20all%20medically,96%25%20from%202009%20to%202015.]of all antibiotics are used on animals in the US with the share rising every year, with similar numbers in other countries with industrialized agriculture systems. Agriculture in India is less industrialized, and only three percent [https://cddep.org/wp-content/uploads/2017/06/india_abx_report-2.pdf] of antibiotics used globally on livestock are used in India. However, antibiotic use in farming is growing rapidly, with antibiotic use expected [https://cddep.org/wp-content/uploads/2017/06/india_abx_report-2.pdf]to more than double over the next decade. Between 2000 and 2018 the percent of chickens showing antibiotic resistance increased [https://thewire.in/health/drug-resistance-in-farm-animals-threatens-human-health-in-india]from 15% to 41%, with over 70% of chicken showing resistance to most antibiotics in Northeast India. It is likely that many bacteria in animals that resistant to antibiotics will have the same effect in humans as well. Finally, India has a massive and rapidly growing [https://wealthofnationspodcast.com/cheap-fast-and-good-enough-how-india-became-the-worlds-pharmacy/] pharmaceuticals industry. Today, 40% [https://www.nytimes.com/2014/02/15/world/asia/medicines-made-in-india-set-off-safety-worries.html]of over the counter medicines in the United States are made in India. Until recently, India had few regulations controlling the disposal of wastewater from pharmaceutical pharmacies. The high but ambient levels of antibiotics in wastewater create an ideal environment [http://Industrial wastewater treatment plant enriches antibiotic resistance genes and alters the structure of microbial communities] for bacteria to gain resistance to antibiotics. Those without access to clean water or who rely upon fish caught from rivers, a disproportionately poor group of people, are especially at risk of getting infected by antibiotic resistant bacteria. The Consequences of Rising Drug Resistance According to the CDDEP, India consistently has some of the highest prevalence of antibiotic resistance in the world. For example [https://resistancemap.cddep.org/AntibioticResistance.php] 87% of Indian enterobacteria are resistance to fluoroquinones as compared to just 5% in the US. Similarly, 84% of E Coli in India is resistant to antibiotics as compared to 34% in the US. One of the consequences of this is that it is increasingly difficult [https://www.chop.edu/news/preventing-antibiotic-resistance-and-spread-superbugs]to use narrow spectrum antibiotics that target specific pathogens in India. Instead broad spectrum antibiotics must be used that often kill helpful gut biome bacteria and can be toxic for children and the elderly. Moreover, many broad spectrum antibiotics are our last line of defense against drug resistant bacteria. One of the AMR bacteria that scare public health experts the most is multi-drug resistant tuberculosis. TB kills nearly 500,000 [https://pubmed.ncbi.nlm.nih.gov/31813430/#:~:text=Abstract,more%20than%201400%20every%20day.] people every year. Currently [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089296/]23% of TB strains in India are resistant to one antibiotic, and 3% resistant to all but the most powerful antibiotics with rates of resistance increasing rapidly. The rise of drug resistant bacteria is a problem not just for India, but for the world. Many drug resistant bacteria can be transmitted from person to person, and across international borders. For example, there has been at least one documented cases [https://thewire.in/health/antimicrobial-resistance-mrsa-st672] of a tourist carrying drug resistant MRSA from India to Paris. The spread of MRSA is especially worrying as studies have found mortality rates anywhere between 15% and 60%, and the rapid growth of MRSA would make any surgical procedure a deadly risk. What Can We DO? Part of controlling the rise of antimicrobial resistance in India is solving India’s broader public health crisis. For example [https://data.worldbank.org/indicator/SH.STA.BASS.ZS] 12% of Brazilians and 15% of Chinese people lacks access to basic sanitation, as opposed to 40% in India. Steps such as better nutrition, prenatal healthcare for mothers, and better access to sanitation all reduce the number of people who need antibiotics in the first place. This both reduces the risk of people catching drug resistant drugs, and for bacteria gaining resistance to antibiotics. It especially important for Indian pharmacies and hospitals to stop prescribing antibiotics unnecessarily, and making sure patients complete their antibiotic courses. Hospitals in particular have emerged as epicenters for antibiotic resistance. My own grandfather lost his live to multidrug resistant antibiotics last year after catching multi-drug resistant pneumonia in an Indian hospital. American hospitals once faced similar problems with antimicrobial resistance. Although the US still sees approximately [https://www.cdc.gov/mmwr/volumes/68/wr/mm6809e1.htm#:~:text=Invasive%20methicillin%2Dresistant%20Staphylococcus%20aureus,of%20decline%20has%20recently%20slowed.&text=Nearly%20120%2C000%20Staphylococcus%20aureus%20bloodstream,the%20United%20States%20in%202017.]20,000 deaths from MRSA a year, the numbers of hospital and community rates of MRSA infection have declined by 74% and 40%. Steps such as regular handwashing, cleaning of all equipment, and proper disposal of waste can all dramatically reduce the rate at which bacteria become resistant to pharmaceuticals in hospital settings. There are likely still far more people in India who die because of a lack of access to antibiotics than people who die from superbugs, and so any restrictionist policies are not tenable. However, in 2017 India’s government, working with the WHO, launched [https://www.bmj.com/content/357/bmj.j2049#:~:text=The%20National%20Action%20Plan%20on,infection%20control%20and%20antimicrobial%20surveillance.]its first National Action Plan on Antimicrobial Resistance. Steps include much greater education for pharmacists and doctors on the risk of drug resistance. The government plans on increasing access to veterinary services to small livestock owners so they have options to treat sick animals other than dousing with antibiotics. While most of these steps involve recommendation and education, the Indian government is also substantially strengthening regulations on the disposal of pharmaceutical factory wastewater. While it is unclear whether these steps will be effective, they mark important first steps. In the long race against bacteria, we’re going to have to go beyond public health measures and develop new antibiotics capable of fighting superbugs. However, the development of new antibiotics suffer massive misaligned incentives. Between [https://www.pewtrusts.org/en/research-and-analysis/reports/2016/05/a-scientific-roadmap-for-antibiotic-discovery]1940 and 1986, 26 new classes of antibiotics were discovered. However [http://A Scientific Roadmap for Antibiotic Discovery], since 1986 not a single new class of antibiotics has been developed. It can take 10 to 15 years and $1 billion to discover a novel antibiotic with a high chance the drug not making it through FDA approval. After drug discovery, it is likely the new antibiotic will be reserved for drug resistant cases, making their use sporadic driving up the price necessary to make drug discovery profitable. Moreover, there is a broader political economy problem that the overwhelming majority of deaths from drug resistant microbes happen in low income countries where neither the government, nor the private sector has the capacity to develop new antibiotics. However, India is an exception to this general principle. In 2020, Wockhardt became the first Indian company to get approval [https://www.business-standard.com/article/companies/wockhardt-becomes-first-indian-company-to-get-nod-for-novel-antibiotics-120011600612_1.html]for a new antibiotic. Moreover, Indian government labs are not only directly conducting research, but working with private companies to accelerate new antibiotic discovery. For example, the Indian government has financed the creation of a biotech incubator [https://www.bloomberg.com/news/features/2018-06-25/the-indian-startups-waging-war-against-superbug-bacteria]aimed at creating health problems faced disproportionately by developing countries by India. Companies created by this incubator include Bugworks, a company that has received from financing from leading global public [https://www.vccircle.com/3one4-capital-backed-biopharma-startup-bugworks-raises-fresh-funding/]and private [https://www.bloomberg.com/news/features/2018-06-25/the-indian-startups-waging-war-against-superbug-bacteria]funds aimed at accelerating antibiotics research. It is likely that the combination of India’s supply of low cost researchers, and government and private sector with a stake in developing antibiotics, India will be at the forefront of solving the antimicrobial resistance problem as well as creating it. The global COVID-19 pandemic has caused [https://www.worldometers.info/coronavirus/]over 2 million recorded deaths, and massive reduction [https://www.imf.org/en/Publications/WEO]in economic activity. It is all but certain that public health authorities across the world will massively increase the resources dedicated to monitoring and containing Coronaviruses. However, it is imperative we extend these resources to other public health threats such as the rise of superbugs. Moreover, making sure the nightmare scenario of 10 million deaths a year requires more than just a one off intervention, but sustained changes in everything from R&D to livestock management to contain. Selected Sources: Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations, World Health Organization Global Trends in Antimicrobial Resistance in Animals in Low- and Middle-Income Countries, Ramanan Laxminarayan Scoping Report on Antimicrobial Resistance in India [https://cddep.org/wp-content/uploads/2017/11/AMR-INDIA-SCOPING-REPORT.pdf], CDDEP Antimicrobial Resistance: Progress in the Decade since Emergence of New Delhi Metallo-β-Lactamase in India [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437806/], Avika Dixit, Neeta Kumar Origins and Evolution of Antibiotic Resistance [https://mmbr.asm.org/content/74/3/417], Julian Davies, Dorothy Davies What drives inappropriate antibiotic dispensing? A mixed-methods study of pharmacy employee perspectives in Haryana, India [https://bmjopen.bmj.com/content/7/3/e013190.abstract], Anna Barker, Kelli Brown NO TIME TO WAIT: SECURING THE FUTURE FROM DRUG-RESISTANT INFECTIONS, World Health Organization [https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1] Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment [https://sfamjournals.onlinelibrary.wiley.com/doi/full/10.1111/j.1462-2920.2006.01054.x], Feliber C Cabello Antibiotic Use and Resistance in Food Animals Current Policy and Recommendations [https://cddep.org/wp-content/uploads/2017/06/india_abx_report-2.pdf], CDDEP Global trends in antimicrobial resistance in animals in low- and middle-income countries, Reshma Silvester [https://thewire.in/health/drug-resistance-in-farm-animals-threatens-human-health-in-india], Julia Wong Industrial wastewater treatment plant enriches antibiotic resistance genes and alters the structure of microbial communities [https://www.sciencedirect.com/science/article/abs/pii/S0043135419305950], Milena Milakovic Why are people dying due to tuberculosis? A study from Alappuzha District [https://pubmed.ncbi.nlm.nih.gov/31813430/#:~:text=Abstract,more%20than%201400%20every%20day.], Kerala, India, M Karthika, Sairu Phillip Antibiotic Resistance, Sanitation, and Public Health , Juliana De Araujo [https://link.springer.com/chapter/10.1007/698_2020_470] Antimicrobial resistance and its containment in India http://origin.searo.who.int/india/topics/antimicrobial_resistance/amr_containment.pdf [http://origin.searo.who.int/india/topics/antimicrobial_resistance/amr_containment.pdf]
180 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Wealth of Nations Podcast community!